• About
  • Subscribe
  • Advertise
  • Contact
Sunday, July 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Business

Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange

by Myles Hume
November 18, 2020
in Business, Company updates & acquisitions, Local, Macular disease, News, Therapies
Reading Time: 2 mins read
A A
The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.

The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.

Share on FacebookShare on Twitter

Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ahead of pivotal Phase 3 trials of its lead drug candidate.

The cash incentive – announced last month – is for research and development costs incurred in the 2019/2020 financial year and follows its debut on a US stock exchange where it reportedly produced the largest initial public offering (IPO) conducted by a development-stage Australian life sciences company.

Its therapy OPT-302 – a VEGF-C/D inhibitor – is being trialled in combination with VEGF-A inhibitors aflibercept (Eylea) and ranibizumab (Lucentis) for nAMD and diabetic macular edema (DME).

Megan Baldwin.

Opthea recently announced it would conduct two concurrent, global, multicentre, randomised, sham-controlled Phase 3 studies evaluating OPT-302 in combination with ranibizumab (Lucentis) or aflibercept (Eylea) for nAMD next year. If successful, OPT-302 could be administered with two approved standard of care VEGF-A inhibitors that had combined sales for retinal diseases of US$11.9 billion ($AU16.3 b) in 2019.

Dr Megan Baldwin, CEO and managing director of Opthea, commented: “This R&D tax incentive credit of $8.5 million further strengthens our balance sheet as Opthea prepares to initiate patient recruitment into pivotal Phase 3 clinical trials of OPT-302 in wet AMD early in 2021.”

The Australian Tax Office’s R&D Tax Incentive is as a Federal Government program under which companies can receive cash incentives for 43.5% of eligible research and development expenditure.

Meanwhile, the ASX-listed firm also recently conducted an IPO on the Manhattan-based Nasdaq stock exchange where it raised US$128.2 million (AU$175 m).

Partners from the international law firm Cooley said they advised Opthea on its IPO of 8,563,300 American Depository Shares. The underwriters have the option to purchase up to an additional 1,425,000 shares.

According to Cooley, Opthea’s Nadsaq debut marked the largest IPO conducted by a development-stage Australian life sciences company, as well as the largest Australian biotech capital raise in a secondary Nasdaq IPO.

More reading

Opthea becomes ASX top 300 company

Opthea meets US and European regulators over Phase 3 trial

Opthea progresses DME trials despite COVID-19 disruption

Tags: afliberceptclinical trialDMEEyleainitial public offeringIPOLucentisnAMDNasdaqOPT-302Optheaphase 3R&Dranibizumabresearch and developmentstock exchangetax creditUS

Related Posts

So many companies working on so many solutions in IOLs and surgery means it has become evident that there is some nomenclature confusion.  Image: Oktay/stock.adobe.com.

Clearing up nomenclature confusion in IOL lenses

by Dr Peter Sumich
July 13, 2025

Presbyopia management has been the holy grail for intraocular lens technology development for 30 years, but sub-classifying lenses has become...

What the customer wants in a frame will not necessarily be suited to the prescription they end up with. Images: Jacobus Boshoff.

No, you can’t have that frame

by Jacobus Boshoff
July 12, 2025

Jacobus Boshoff on why a good optical dispenser sometimes needs to dish out the harsh truth, and why frame choice...

Myopia is surging around the world, and particularly among children. New studies show that HOYA's DIMS technology can have a lasting impact in treatment. Image: HOYA.

New evidence backs HOYA’s DIMS technology to combat myopia

by Staff Writer
July 11, 2025

HOYA Vision Care has announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited